Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice

作者：Loryn J. Bohne, Hailey J. Jansen, Tristan W. Dorey, Irene M. Daniel, K. Lockhart Jamieson, Darrell D. Belke, Megan D. McRae, Robert A. Rose · 发表于：JACC Basic to Translational Science · 年份：2023 · DOI：10.1016/j.jacbts.2023.01.005 · 被引用次数：57 · 研究领域：Atrial Fibrillation Management and Outcomes、Diabetes Treatment and Management、Cardiovascular Function and Risk Factors

Atrial fibrillation (AF) is highly prevalent in type 2 diabetes where it increases morbidity and mortality. Glucagon-like peptide (GLP)-1 receptor agonists are used in the treatment of type 2 diabetes (T2DM), but their effects on AF in T2DM are poorly understood. The present study demonstrates type 2 diabetic db/db mice are highly susceptible to AF in association with atrial electrical and structural remodeling. GLP-1, as well as the long-acting GLP-1 analogue liraglutide, reduced AF and prevented atrial remodeling in db/db mice. These data suggest that GLP-1 and related analogues could protect against AF in patients with T2DM.